{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T05:32:41Z","timestamp":1741239161549,"version":"3.38.0"},"reference-count":36,"publisher":"Tech Science Press","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["OR"],"published-print":{"date-parts":[[2024]]},"DOI":"10.32604\/or.2023.030770","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T09:23:50Z","timestamp":1698744230000},"page":"325-337","source":"Crossref","is-referenced-by-count":0,"title":["Identification of <i>TNFRSF1A<\/i> as a novel regulator of carfilzomib resistance in multiple myeloma"],"prefix":"10.32604","volume":"32","author":[{"given":"JIE","family":"ZHAO","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"XUANTAO","family":"YANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HAIXI","family":"ZHANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"XUEZHONG","family":"GU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"17807","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: A review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1182\/blood.2019000241","article-title":"Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma","volume":"134","author":"Rosi\u00f1ol","year":"2019","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1158\/1055-9965.EPI-21-0904","article-title":"Associations between alcohol consumption patterns and risk of multiple myeloma: A nationwide cohort study in South Korea","volume":"31","author":"Jeon","year":"2022","journal-title":"Cancer Epidemiology, Biomarkers & Prevention"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1158\/1055-9965.EPI-19-0389","article-title":"Association of BMI, smoking, and alcohol with multiple myeloma mortality in Asians: A pooled analysis of more than 800,000 participants in the Asia Cohort Consortium","volume":"28","author":"Ugai","year":"2019","journal-title":"Cancer ePidemiology, Biomarkers & Prevention"},{"key":"ref5","first-page":"107815522211325","article-title":"Investigation of the frequency of bortezomib neuropathy in patients with multiple myeloma diagnosis with normal and abnormal genetic characteristics","volume":"91","author":"Kul","year":"2022","journal-title":"Journal of Oncology Pharmacy Practice"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"374","DOI":"10.14715\/cmb\/2022.68.3.41","article-title":"Magnetic resonance imaging combined with computed tomography in the diagnosis of multiple myeloma and the killing effect of doxorubicin nano-drug delivery system on myeloma cells","volume":"68","author":"Liao","year":"2022","journal-title":"Cellular and Molecular Biology"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.3390\/cancers14194741","article-title":"Multiple myeloma in patients over 80: A real world retrospective study of first line conservative approach with bortezomib dexamethasone doublet therapy and mini-review of literature","volume":"14","author":"Huynh","year":"2022","journal-title":"Cancers"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41571-018-0002-6","article-title":"The emerging clinical relevance of genomics in cancer medicine","volume":"15","author":"Berger","year":"2018","journal-title":"Nature Reviews Clinical Oncology"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1158\/1535-7163.MCT-11-0433","article-title":"Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma","volume":"10","author":"Hideshima","year":"2011","journal-title":"Molecular Cancer Therapeutics"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.2147\/CMAR.S150653","article-title":"Carfilzomib for relapsed and refractory multiple myeloma","volume":"11","author":"Groen","year":"2019","journal-title":"Cancer Management and Research"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"740796","DOI":"10.3389\/fonc.2021.740796","article-title":"Carfilzomib: A promising proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma","volume":"11","author":"Jayaweera","year":"2021","journal-title":"Frontiers in Oncology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/s41591-021-01232-w","article-title":"Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing","volume":"27","author":"Cohen","year":"2021","journal-title":"Nature Medicine"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"106499","DOI":"10.1016\/j.leukres.2020.106499","article-title":"Up-regulation of multidrug resistance protein MDR1\/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs","volume":"101","author":"Byrgazov","year":"2021","journal-title":"Leukemia Research"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/ajt.15634","article-title":"Proteasomal adaptations underlying carfilzomib-resistance in human bone marrow plasma cells","volume":"20","author":"Woodle","year":"2020","journal-title":"American Journal of Transplantation"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41375-019-0517-6","article-title":"Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma","volume":"33","author":"Landgren","year":"2019","journal-title":"Leukemia"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3390\/cancers13040625","article-title":"The immune microenvironment in multiple myeloma: Friend or foe?","volume":"13","author":"Lopes","year":"2021","journal-title":"Cancers"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13045-022-01234-2","article-title":"Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma","volume":"15","author":"Swamydas","year":"2022","journal-title":"Journal of Hematology & Oncology"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"5562630","DOI":"10.1155\/2021\/5562630","article-title":"Selective cytotoxicity of single and dual anti-CD19 and anti-CD138 chimeric antigen receptor-natural killer cells against hematologic malignancies","volume":"2021","author":"Luanpitpong","year":"2021","journal-title":"Journal of Immunology Research"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: A single-arm, phase 2 trial","volume":"6","author":"Yan","year":"2019","journal-title":"The Lancet Haematology"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.gene.2019.03.046","volume":"700","author":"Hu","year":"2019","journal-title":"Gene"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.3109\/07357900902769749","article-title":"Cell adhesion molecules: Role and clinical significance in cancer","volume":"27","author":"Makrilia","year":"2009","journal-title":"Cancer Investigation"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jocn.2021.01.019","article-title":"A retrospective analysis of GSE84010: Cell adhesion molecules might contribute to bevacizumab resistance in glioblastoma","volume":"86","author":"Fu","year":"2021","journal-title":"Journal of Clinical Neuroscience"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1002\/cbin.11598","article-title":"Epithelial cell adhesion molecule promotes breast cancer resistance protein-mediated multidrug resistance in breast cancer by inducing partial epithelial-mesenchymal transition","volume":"45","author":"Shi","year":"2021","journal-title":"Cell Biology International"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/onc.2008.385","article-title":"Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma","volume":"28","author":"Noborio-Hatano","year":"2009","journal-title":"Oncogene"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"e14502","DOI":"10.15252\/emmm.202114502","article-title":"Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer","volume":"14","author":"Zhou","year":"2022","journal-title":"EMBO Molecular Medicine"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1182\/blood.2019000722","article-title":"Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"134","author":"Chari","year":"2019","journal-title":"Blood"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood.2020009856","article-title":"RAR\u03b3 activation sensitizes human myeloma cells to carfilzomib treatment through the OAS-RNase L innate immune pathway","volume":"139","author":"Wang","year":"2022","journal-title":"Blood"},{"key":"ref29","first-page":"3213","article-title":"Mechanisms of immune evasion in multiple myeloma","volume":"13","author":"Botta","year":"2021","journal-title":"Open Questions and Therapeutic Opportunities. Cancers"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3389\/fimmu.2019.01078","article-title":"Cell adhesion molecules and their roles and regulation in the immune and tumor microenvironment","volume":"10","author":"Harjunp\u00e4\u00e4","year":"2019","journal-title":"Frontiers in Immunology"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"656908","DOI":"10.3389\/fimmu.2021.656908","article-title":"The role of tumor necrosis factor in manipulating the immunological response of tumor microenvironment","volume":"12","author":"Laha","year":"2021","journal-title":"Frontiers in Immunology"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/10552","article-title":"Mice deficient in tumor necrosis factor-\u03b1 are resistant to skin carcinogenesis","volume":"5","author":"Moore","year":"1999","journal-title":"Nature Medicine"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.3389\/fimmu.2019.01818","article-title":"The TNF paradox in cancer progression and immunotherapy","volume":"10","author":"Montfort","year":"2019","journal-title":"Frontiers in Immunology"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1182\/blood.V98.4.1108","article-title":"Tumor necrosis factor-\u03b1 induces coordinated changes in major histocompatibility class I presentation pathway, resulting in increased stability of class I complexes at the cell surface","volume":"98","author":"Hallermalm","year":"2001","journal-title":"Blood"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"12953","DOI":"10.1038\/s41598-017-13072-1","article-title":"Danshenol A inhibits TNF-\u03b1-induced expression of intercellular adhesion molecule-1 (ICAM-1) mediated by NOX4 in endothelial cells","volume":"7","author":"Zhao","year":"2017","journal-title":"Scientific Reports"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1080\/10428194.2022.2087064","article-title":"Investigating the potential molecular players and therapeutic drug molecules in carfilzomib resistant multiple myeloma by comprehensive bioinformatics analysis","volume":"63","author":"Ghosal","year":"2022","journal-title":"Leukemia & Lymphoma"}],"container-title":["Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.techscience.com\/files\/or\/2024\/TSP_OR-32-2\/OncolRes-32-02-30770\/OncolRes-32-30770.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:56:40Z","timestamp":1741222600000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.techscience.com\/or\/v32n2\/55082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024]]},"published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.32604\/or.2023.030770","relation":{},"ISSN":["1555-3906"],"issn-type":[{"type":"electronic","value":"1555-3906"}],"subject":[],"published":{"date-parts":[[2024]]}}}